Entera Bio (ENTX) Q3 2025 earnings summary

Executive summary

• Focused on developing first-in-class oral peptide therapies for chronic conditions, with lead candidates EB613 for osteoporosis and EB612 for hypoparathyroidism, and collaborations for oral GLP-1/glucagon and GLP-2 programs targeting obesity and rare GI diseases.

• Achieved FDA agreement on BMD as the primary endpoint for the pivotal Phase 3 study of EB613, supporting a future NDA submission.

• Advanced EB613 to a planned Phase 3 trial after FDA agreement; new generation of EB613 and OXM (GLP-1/glucagon) programs progressing with OPKO collaboration.

• Presented strong Phase 2 data for EB613, showing rapid and significant bone density improvements in postmenopausal women, including younger high-risk groups.

• No product sales to date; revenue derived from research services and collaboration agreements.

Financial highlights

• Net loss for Q3 2025 was $3.2 million, up 6% year-over-year; nine-month net loss was $8.4 million, up 17% year-over-year.

• Cash and cash equivalents plus restricted cash totaled $16.6 million as of September 30, 2025, with $8.0 million restricted for OPKO collaboration.

• Operating losses for Q3 and nine months ended September 30, 2025 were $3.3 million and $8.5 million, respectively.

• Research and development expenses were $1.6 million, up $0.1 million year-over-year, reflecting Phase 3 preparation for EB613.

• General and administrative expenses were $1.6 million, up from $1.5 million in the prior-year quarter.

Outlook and guidance

• Current cash resources expected to fund operations through mid-Q3 2026, excluding the initiation of EB613 Phase 3, which requires additional funding.

• Next-generation EB613 Phase 1 trial remains on track for late 2025 initiation.

• IND for oral OXM in obesity planned for H1 2026.

• First PK/PD preclinical data for EB612 in hypoparathyroidism expected by year-end 2025.

• Ongoing evaluation of financing alternatives; future capital needs depend on clinical progress and potential collaborations.